Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 152

1.

Loss of microbicidal activity and increased formation of biofilm due to decreased lactoferrin activity in patients with cystic fibrosis.

Rogan MP, Taggart CC, Greene CM, Murphy PG, O'Neill SJ, McElvaney NG.

J Infect Dis. 2004 Oct 1;190(7):1245-53.

2.

Iron-binding compounds impair Pseudomonas aeruginosa biofilm formation, especially under anaerobic conditions.

O'May CY, Sanderson K, Roddam LF, Kirov SM, Reid DW.

J Med Microbiol. 2009 Jun;58(Pt 6):765-73. doi: 10.1099/jmm.0.004416-0.

PMID:
19429753
3.

Relationship between antimicrobial proteins and airway inflammation and infection in cystic fibrosis.

Sagel SD, Sontag MK, Accurso FJ.

Pediatr Pulmonol. 2009 Apr;44(4):402-9. doi: 10.1002/ppul.21028.

PMID:
19283840
4.
5.
6.
7.

Bismuth-thiol incorporation enhances biological activities of liposomal tobramycin against bacterial biofilm and quorum sensing molecules production by Pseudomonas aeruginosa.

Halwani M, Hebert S, Suntres ZE, Lafrenie RM, Azghani AO, Omri A.

Int J Pharm. 2009 May 21;373(1-2):141-6. doi: 10.1016/j.ijpharm.2009.02.001.

PMID:
19429299
8.

Cleavage of lymphocyte surface antigens CD2, CD4, and CD8 by polymorphonuclear leukocyte elastase and cathepsin G in patients with cystic fibrosis.

Döring G, Frank F, Boudier C, Herbert S, Fleischer B, Bellon G.

J Immunol. 1995 May 1;154(9):4842-50.

PMID:
7722333
9.
10.

Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients.

Bjarnsholt T, Jensen PØ, Fiandaca MJ, Pedersen J, Hansen CR, Andersen CB, Pressler T, Givskov M, Høiby N.

Pediatr Pulmonol. 2009 Jun;44(6):547-58. doi: 10.1002/ppul.21011.

PMID:
19418571
11.

Evaluation of long-term co-administration of tobramycin and clarithromycin in a mature biofilm model of cystic fibrosis clinical isolates of Pseudomonas aeruginosa.

Tré-Hardy M, Traore H, El Manssouri N, Vanderbist F, Vaneechoutte M, Devleeschouwer MJ.

Int J Antimicrob Agents. 2009 Oct;34(4):370-4. doi: 10.1016/j.ijantimicag.2009.04.010.

PMID:
19505804
12.

P. aeruginosa Biofilms in CF Infection.

Wagner VE, Iglewski BH.

Clin Rev Allergy Immunol. 2008 Dec;35(3):124-34. doi: 10.1007/s12016-008-8079-9. Review.

PMID:
18509765
13.

Pseudomonas aeruginosa chronic colonization in cystic fibrosis patients.

Murray TS, Egan M, Kazmierczak BI.

Curr Opin Pediatr. 2007 Feb;19(1):83-8. Review.

PMID:
17224667
14.

Microcolony formation: a novel biofilm model of Pseudomonas aeruginosa for the cystic fibrosis lung.

Sriramulu DD, Lünsdorf H, Lam JS, Römling U.

J Med Microbiol. 2005 Jul;54(Pt 7):667-76.

PMID:
15947432
15.

Use of the rotating wall vessel technology to study the effect of shear stress on growth behaviour of Pseudomonas aeruginosa PA01.

Crabbé A, De Boever P, Van Houdt R, Moors H, Mergeay M, Cornelis P.

Environ Microbiol. 2008 Aug;10(8):2098-110. doi: 10.1111/j.1462-2920.2008.01631.x.

PMID:
18430020
16.

Antibiotic susceptabilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions.

Hill D, Rose B, Pajkos A, Robinson M, Bye P, Bell S, Elkins M, Thompson B, Macleod C, Aaron SD, Harbour C.

J Clin Microbiol. 2005 Oct;43(10):5085-90.

17.

Neutrophil mediators, Pseudomonas, and pulmonary dysfunction in cystic fibrosis.

Meyer KC, Zimmerman J.

J Lab Clin Med. 1993 May;121(5):654-61.

PMID:
8386737
18.

Biofilm differentiation and dispersal in mucoid Pseudomonas aeruginosa isolates from patients with cystic fibrosis.

Kirov SM, Webb JS, O'may CY, Reid DW, Woo JK, Rice SA, Kjelleberg S.

Microbiology. 2007 Oct;153(Pt 10):3264-74.

PMID:
17906126
19.

Pseudomonas aeruginosa hypoxic or anaerobic biofilm infections within cystic fibrosis airways.

Hassett DJ, Sutton MD, Schurr MJ, Herr AB, Caldwell CC, Matu JO.

Trends Microbiol. 2009 Mar;17(3):130-8. doi: 10.1016/j.tim.2008.12.003. Review.

PMID:
19231190
20.

Pseudomonas aeruginosa anaerobic respiration in biofilms: relationships to cystic fibrosis pathogenesis.

Yoon SS, Hennigan RF, Hilliard GM, Ochsner UA, Parvatiyar K, Kamani MC, Allen HL, DeKievit TR, Gardner PR, Schwab U, Rowe JJ, Iglewski BH, McDermott TR, Mason RP, Wozniak DJ, Hancock RE, Parsek MR, Noah TL, Boucher RC, Hassett DJ.

Dev Cell. 2002 Oct;3(4):593-603.

Items per page

Supplemental Content

Support Center